Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 2.

Gastrointestinal Symptom Rating Scale Upper Abdominal Symptom Score Changes From Baseline After 6 Weeks and 12 Weeks of Administration

Variable Time NOVAponin Placebo P-value
Total Score 6 wk-baseline –5.13 ± 0.55 –1.92 ± 0.44 < 0.001a
12 wk-baseline –5.30 ± 0.60 –2.35 ± 0.56 < 0.001a
Upper abdominal pain 6 wk-baseline –0.79 ± 0.10 –0.14 ± 0.14 < 0.001a
12 wk-baseline –0.70 ± 0.12 –0.22 ± 0.13 0.005b
Heartburn 6 wk-baseline –0.52 ± 0.11 –0.10 ± 0.12 0.003b
12 wk-baseline –0.56 ± 0.11 –0.20 ± 0.11 0.018c
Acid reflux 6 wk-baseline –0.93 ± 0.12 –0.63 ± 0.14 0.214
12 wk-baseline –0.93 ± 0.13 –0.67 ± 0.14 0.185
Hunger pain 6 wk-baseline –0.36 ± 0.13 –0.04 ± 0.10 0.021c
12 wk-baseline –0.52 ± 0.11 –0.25 ± 0.09 0.104
Nausea 6 wk-baseline –0.46 ± 0.09 –0.35 ± 0.11 0.496
12 wk-baseline –0.48 ± 0.10 –0.37 ± 0.10 0.485
Rumbling 6 wk-baseline –0.64 ± 0.12 –0.25 ± 0.14 0.025c
12 wk-baseline –0.66 ± 0.12 –0.31 ± 0.15 0.066
Bloating 6 wk-baseline –0.77 ± 0.12 –0.16 ± 0.13 0.001b
12 wk-baseline –0.84 ± 0.14 –0.14 ± 0.15 < 0.001a
Burping 6 wk-baseline –0.66 ± 0.12 –0.25 ± 0.11 0.019c
12 wk-baseline –0.61 ± 0.12 –0.20 ± 0.14 0.033c

aP < 0.001, bP < 0.01, cP < 0.05; compared between groups: P-value for 2 sample t test or Wilcoxon rank sum test.

Data are presented as mean ± SE.
J Neurogastroenterol Motil 2024;30:468~479 https://doi.org/10.5056/jnm23180
© J Neurogastroenterol Motil